Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry refers to a combination therapy of propofol with an analgesic drug, commonly used for procedural sedation and anesthesia. Propofol is an intravenous anesthetic agent that acts primarily as a positive allosteric modulator of the GABA-A receptor, producing sedation and hypnosis. It has rapid onset and offset due to its high lipid solubility and redistribution kinetics. Analgesics frequently combined with propofol include opioids such as fentanyl, remifentanil, or alfentanil (mu-opioid receptor agonists), or dissociative anesthetics like ketamine (NMDA receptor antagonist). The combination allows for synergistic effects—propofol provides hypnosis/sedation while the analgesic addresses pain—enabling lower doses of each agent to be used, which can reduce side effects such as hypotension or respiratory depression[1][6][7]. This approach is widely utilized in emergency medicine and anesthesia for procedures requiring both sedation and pain control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propofol + analgesic drug.